It’s a big day for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares are shooting up 35% faster than Jack’s magic bean sparking right into a giant beanstalk.
Arena Pharmaceuticals, Inc. Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors have a smile on their faces Monday evening, after the drug maker announced positive Phase 2 results for …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in …
In a research report published Wednesday, FBR analyst Rahul Jasuja reiterated an Outperform rating on shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) with a …
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported financial results for the fourth quarter and full-year ended December 31, 2016 and provided a corporate update.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has amended its BELVIQ (lorcaserin HCl) marketing and supply agreement with Eisai Co.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that it has completed enrollment in the ralinepag phase 2 trial.
